Pressmeddelanden, rapporter och bolagsmeddelande för Empros Pharma AB

Empros Pharma AB, a biopharmaceutical company based in Stockholm, announced positive results from its Phase 2 POEM study, which showed improved tolerability for its investigational drug EMP16 when combined with dietary support. EMP16, a combination of orlistat and acarbose, is being developed as a long-term weight-loss maintenance therapy. The POEM study results, along with strong efficacy data from previous trials (LEAAP and SESAM), position EMP16 as a promising option in a market with no approved weight-loss maintenance therapeutics, estimated to be worth over $100 billion. Empros plans to advance EMP16 into further trials. The company highlights the unmet need for sustainable weight-loss maintenance solutions, as many patients discontinue current anti-obesity medications and regain lost weight. Empros Pharma was founded in 2013 and is exploring investment and partnership opportunities for EMP16.

Swedish biopharma company, Empros Pharma, has reported positive topline data from its phase 2b trial for EMP16, an oral therapy for obesity and long-term weight management. The trial demonstrated that a third of patients lost at least 10% of their body weight, with some losing up to 23%. The average weight loss was around 8%. The successful completion of this trial brings Empros Pharma closer to market and the firm is now set to initiate phase 3 trials with a potential launch in 2027. Empros Pharma is seeking pharma partners or investors for the next phase. The company's CEO, Arvid Söderhall, highlighted the need for long-term, affordable, and tolerable weight management solutions like EMP16 in the market.